JP2010527375A5 - - Google Patents

Download PDF

Info

Publication number
JP2010527375A5
JP2010527375A5 JP2010508596A JP2010508596A JP2010527375A5 JP 2010527375 A5 JP2010527375 A5 JP 2010527375A5 JP 2010508596 A JP2010508596 A JP 2010508596A JP 2010508596 A JP2010508596 A JP 2010508596A JP 2010527375 A5 JP2010527375 A5 JP 2010527375A5
Authority
JP
Japan
Prior art keywords
gpr12
long
term memory
memory formation
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010508596A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010527375A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/063804 external-priority patent/WO2008144453A1/en
Publication of JP2010527375A publication Critical patent/JP2010527375A/ja
Publication of JP2010527375A5 publication Critical patent/JP2010527375A5/ja
Pending legal-status Critical Current

Links

JP2010508596A 2007-05-15 2008-05-15 Gpr12の阻害による認知障害の治療方法 Pending JP2010527375A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93816307P 2007-05-15 2007-05-15
PCT/US2008/063804 WO2008144453A1 (en) 2007-05-15 2008-05-15 Methods of treating cognitive disorders by inhibition of gpr12

Publications (2)

Publication Number Publication Date
JP2010527375A JP2010527375A (ja) 2010-08-12
JP2010527375A5 true JP2010527375A5 (enExample) 2011-06-23

Family

ID=40122145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010508596A Pending JP2010527375A (ja) 2007-05-15 2008-05-15 Gpr12の阻害による認知障害の治療方法

Country Status (11)

Country Link
US (2) US7968524B2 (enExample)
EP (1) EP2162137B1 (enExample)
JP (1) JP2010527375A (enExample)
KR (1) KR20100029079A (enExample)
CN (1) CN101808647A (enExample)
AU (1) AU2008254905A1 (enExample)
BR (1) BRPI0811625A2 (enExample)
CA (1) CA2684920A1 (enExample)
IL (1) IL202091A0 (enExample)
MX (1) MX2009012316A (enExample)
WO (1) WO2008144453A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102458435A (zh) 2009-04-09 2012-05-16 考格尼申治疗股份有限公司 认知衰退的抑制剂
SG178191A1 (en) 2009-07-31 2012-03-29 Cognition Therapeutics Inc Inhibitors of cognitive decline
WO2011106785A2 (en) * 2010-02-26 2011-09-01 Cognition Therapeutics, Inc. Methods of identifying agents effective to treat cognitive decline and diseases associated therewith
CN103458885B (zh) 2011-02-02 2016-02-10 考格尼申治疗股份有限公司 由姜黄油分离的化合物及使用方法
JP6517827B2 (ja) 2014-01-31 2019-05-22 コグニション セラピューティクス,インコーポレイテッド イソインドリン組成物および神経変性疾患の治療方法
CA3061787A1 (en) 2017-05-15 2018-11-22 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
BR102022009685A2 (pt) * 2022-05-18 2023-11-28 Fundação Oswaldo Cruz Método para triagem de fármacos ou substâncias com potencial neuroprotetor, kit para triagem de fármacos ou substâncias, e, uso de um painel de genes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100334858B1 (ko) 1993-02-19 2006-01-27 니뽄 신야쿠 가부시키가이샤 핵산공중합체를함유하는의약조성물
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5877399A (en) * 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
EP0755454B1 (en) 1994-04-13 2008-02-13 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US6653086B1 (en) * 1998-04-14 2003-11-25 Arena Pharmaceuticals, Inc. Endogenous constitutively activated G protein-coupled orphan receptors
EP1240199A2 (en) * 1999-12-10 2002-09-18 AstraZeneca AB Method for screening of appetite control agents
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US20060247194A1 (en) 2000-08-30 2006-11-02 Sirna Therapeutics , Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
RU2322500C2 (ru) * 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
US6586524B2 (en) 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
US20040023384A1 (en) * 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of G protein-coupled receptor 12 expression
US20050106731A1 (en) 2002-08-05 2005-05-19 Davidson Beverly L. siRNA-mediated gene silencing with viral vectors
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
WO2004038407A2 (en) * 2002-10-24 2004-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US20070104688A1 (en) 2003-02-13 2007-05-10 City Of Hope Small interfering RNA mediated transcriptional gene silencing in mammalian cells
CA2539127A1 (en) * 2003-09-19 2005-03-31 Paradigm Therapeutics Limited Receptor
EP1745295B1 (en) * 2004-04-20 2010-10-06 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production

Similar Documents

Publication Publication Date Title
Jeong et al. Activation of temperature-sensitive TRPV1-like receptors in ARC POMC neurons reduces food intake
JP2010527375A5 (enExample)
Ng et al. Indoxyl sulfate downregulates expression of Mas receptor via OAT3/AhR/Stat3 pathway in proximal tubular cells
Cui et al. Astroglial Kir4. 1 in the lateral habenula drives neuronal bursts in depression
Crossland et al. Focal adhesion kinase is required for IGF-I-mediated growth of skeletal muscle cells via a TSC2/mTOR/S6K1-associated pathway
Bonito-Oliva et al. A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions
Beggiato et al. Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo
Couillard-Despres et al. Ageing abolishes the effects of fluoxetine on neurogenesis
Kilduff et al. Activation of cortical interneurons during sleep: an anatomical link to homeostatic sleep regulation?
Ma et al. Negative pressure wound therapy promotes vessel destabilization and maturation at various stages of wound healing and thus influences wound prognosis
JP2017538671A5 (enExample)
Moaddab et al. Oxytocin receptor neurotransmission in the dorsolateral bed nucleus of the stria terminalis facilitates the acquisition of cued fear in the fear-potentiated startle paradigm in rats
Su et al. Injection of corticotropin‐releasing hormone into the amygdala aggravates visceral nociception and induces noradrenaline release in rats
Flandreau et al. Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala
Munari et al. Selective brain region activation by histamine H3 receptor antagonist/inverse agonist ABT-239 enhances acetylcholine and histamine release and increases c-Fos expression
WO2010036918A3 (en) Intracellular dna receptor
Raudensky et al. Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function
Xin et al. Neuron-astrocyte coupling in lateral habenula mediates depressive-like behaviors
Roberts et al. Dopamine release in nucleus accumbens is under tonic inhibition by adenosine A1 receptors regulated by astrocytic ENT1 and dysregulated by ethanol
Xing et al. Acid‐sensing ion channel subtype 3 function and immunolabelling increases in skeletal muscle sensory neurons following femoral artery occlusion
Yoshizumi et al. Valproate prevents dysregulation of spinal glutamate and reduces the development of hypersensitivity in rats after peripheral nerve injury
JP2016528914A5 (enExample)
Voelkl et al. SGK1-sensitive regulation of cyclin-dependent kinase inhibitor 1B (p27) in cardiomyocyte hypertrophy
Bancroft et al. Extracellular S100B inhibits A‐type voltage‐gated potassium currents and increases L‐type voltage‐gated calcium channel activity in dopaminergic neurons
Campelo et al. AMPAR-dependent synaptic plasticity initiates cortical remapping and adaptive behaviors during sensory experience